Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kevin Forrest | M | 47 |
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | 4 years |
Sharif Tabebordbar | M | - |
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | 3 years |
Beth Seidenberg | M | 67 |
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | - |
Clare Ozawa | M | 50 |
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Fielden
- Personal Network